Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.67 |
| ▸ | MET | P08581 | 1/20 | 0.67 |
| ▸ | NQO2 | P16083 | 1/20 | 0.67 |
| ▸ | FECH | P22830 | 1/20 | 0.67 |
| ▸ | CLK3 | P49761 | 1/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827335 | 1.00 | PLK1 (0.67) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3230100 | 0.90 | PLK1 (0.54) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3230160 | 0.90 | PLK1 (0.54) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3240577 | 0.88 | PLK1 (0.52) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3240622 | 0.88 | PLK1 (0.52) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3236089 | 0.87 | PLK1 (0.52) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3236085 | 0.87 | PLK1 (0.52) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3241317 | 0.85 | PLK1 (0.50) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3236806 | 0.85 | PLK1 (0.50) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3241287 | 0.85 | PLK1 (0.50) | PLK1METNQO2FECHCLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689706-B1 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIV - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-11 | — | — | EP | claimed |
| EP-1896401-B1 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | UNIV TEMPLE (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2012020961-A3 | PASTE FOR CONTACTS AND SOLAR CELL USING THE SAME | LG INNOTEK CO., LTD. (KR) | 2012-05-10 | — | — | WO | claimed |
| EP-1841420-B1 | TREATMENT OF DRUG-RESISTANT PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-12-07 | — | — | EP | claimed |
| US-7744889-B2 | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-06-29 | — | — | US | claimed |
| US-20090306207-A1 | Treatment of Drug-Resistant Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2009-12-10 | — | — | US | claimed |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-14 | — | — | US | claimed |
| EP-1896401-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | Temple University of the Commonwealth System of Higher Education (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1689706-A4 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2007-11-14 | — | — | EP | claimed |
| US-20060280746-A1 | (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents | ONCONOVA THERAPEUTICS INC. | 2006-12-14 | — | — | US | claimed |
| WO-2006091870-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-08-31 | — | — | WO | claimed |
| EP-1689706-A2 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2005046599-A2 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-05-26 | — | — | WO | claimed |
| EP-1689706-B1 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIV - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-1896401-B1 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | UNIV TEMPLE (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012020961-A3 | PASTE FOR CONTACTS AND SOLAR CELL USING THE SAME | LG INNOTEK CO., LTD. (KR) | 2012-05-10 | — | — | WO | disclosed |
| US-20060280746-A1 | (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents | ONCONOVA THERAPEUTICS INC. | 2006-12-14 | — | — | US | disclosed |
| EP-1689706-A2 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006074149-A2 | TREATMENT OF DRUG-RESISTANT PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005046599-A2 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060280746-A1 | (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents | SULT1E1, GSTO1, CCNA1 | PLK1 2269/4885MET 2189/4885NQO2 1888/4885 |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | SULT2A1, SULT1A1, ARSA | PLK1 4666/4885MET 2563/4885NQO2 1199/4885 |
| US-20090306207-A1 | Treatment of Drug-Resistant Proliferative Disorders | ARSA, KSR1, RPS6KA1 | PLK1 1291/4885MET 2961/4885NQO2 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.